A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features
Phase of Trial: Phase III
Latest Information Update: 07 Aug 2018
At a glance
- Drugs Lurasidone (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms RESOLVE-1
- Sponsors Sunovion Pharmaceuticals
- 07 Aug 2018 Results published in the Journal of Clinical Psychiatry.
- 20 Sep 2016 Results of post hoc analysis evaluating the impact of baseline depression severity on treatment response presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
- 20 Sep 2016 Results of post-hoc analysis, presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.